Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS).
Koskinas KC, Windecker S, Pedrazzini G, Mueller C, Cook S, Matter CM, Muller O, Häner J, Gencer B, Crljenica C, Amini P, Deckarm O, Iglesias JF, Räber L, Heg D, Mach F. Koskinas KC, et al. J Am Coll Cardiol. 2019 Nov 19;74(20):2452-2462. doi: 10.1016/j.jacc.2019.08.010. Epub 2019 Aug 31. J Am Coll Cardiol. 2019. PMID: 31479722 Free article. Clinical Trial.
Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors.
Butty A, Gencer B, Koskinas KC, Carballo D, Räber L, Klingenberg R, Matter CM, Lüscher TF, Windecker S, Muller O, Rodondi N, Mach F, Nanchen D. Butty A, et al. Among authors: koskinas kc. Int J Cardiol. 2020 Jan 15;299:289-295. doi: 10.1016/j.ijcard.2019.10.012. Epub 2019 Oct 9. Int J Cardiol. 2020. PMID: 31668506
Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort.
Gencer B, Carballo D, Nanchen D, Koskinas KC, Klingenberg R, Räber L, Auer R, Carballo S, Heg D, Windecker S, Lüscher TF, Matter CM, Rodondi N, Mach F. Gencer B, et al. Among authors: koskinas kc. Int J Cardiol. 2020 Mar 15;303:8-13. doi: 10.1016/j.ijcard.2019.12.011. Epub 2019 Dec 10. Int J Cardiol. 2020. PMID: 31859113 Clinical Trial.
Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
Zanchin C, Koskinas KC, Ueki Y, Losdat S, Häner JD, Bär S, Otsuka T, Inderkum A, Jensen MRJ, Lonborg J, Fahrni G, Ondracek AS, Daemen J, van Geuns RJ, Iglesias JF, Matter CM, Spirk D, Juni P, Mach F, Heg D, Engstrom T, Lang I, Windecker S, Räber L. Zanchin C, et al. Among authors: koskinas kc. Am Heart J. 2021 Aug;238:33-44. doi: 10.1016/j.ahj.2021.04.006. Epub 2021 May 2. Am Heart J. 2021. PMID: 33951415 Clinical Trial.
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.
Räber L, Ueki Y, Otsuka T, Losdat S, Häner JD, Lonborg J, Fahrni G, Iglesias JF, van Geuns RJ, Ondracek AS, Radu Juul Jensen MD, Zanchin C, Stortecky S, Spirk D, Siontis GCM, Saleh L, Matter CM, Daemen J, Mach F, Heg D, Windecker S, Engstrøm T, Lang IM, Koskinas KC; PACMAN-AMI collaborators. Räber L, et al. Among authors: koskinas kc. JAMA. 2022 May 10;327(18):1771-1781. doi: 10.1001/jama.2022.5218. JAMA. 2022. PMID: 35368058 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 32689834
Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines.
Koskinas KC, Gencer B, Nanchen D, Branca M, Carballo D, Klingenberg R, Blum MR, Carballo S, Muller O, Matter CM, Lüscher TF, Rodondi N, Heg D, Wilhelm M, Räber L, Mach F, Windecker S. Koskinas KC, et al. Eur J Prev Cardiol. 2021 Mar 23;28(1):59-65. doi: 10.1177/2047487320940102. Epub 2020 Jul 20. Eur J Prev Cardiol. 2021. PMID: 33755142
136 results